Clinical and Experimental Medicine

, Volume 19, Issue 2, pp 173–181 | Cite as

Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm

  • Yue Wu
  • Fei Fei Liu
  • Yao Xu
  • Jing Jing Wang
  • Sama Samadli
  • Yang Fang Wu
  • Hui Hui Liu
  • Wei Xia Chen
  • Huang Huang Luo
  • Dong Dong Zhang
  • Wei Wei
  • Peng HuEmail author
Original Article


Kawasaki disease (KD) is an acute, systemic vasculitis and occurs mainly in childhood. Interleukin-6 (IL-6) is a pleiotropic cytokine synthesized predominantly by neutrophils and monocytes/macrophages and plays an important role in systemic inflammatory disease. However, a little information is currently available on the relationship of serum IL-6 with conventional inflammatory mediators, clinical classification, IVIG response and coronary artery aneurysm (CAA). 165 Chinese children with KD were enrolled and divided into six subgroups, including complete KD, incomplete KD, IVIG-responsive KD, IVIG-nonresponsive KD, coronary artery noninvolvement KD and coronary artery involvement KD. Blood samples were collected from all subjects within 24-h pre- and 48-h post-IVIG therapy, respectively. Serum IL-6 and conventional inflammatory mediators were detected. (1) Serum IL-6 markedly increased in the acute phase of KD, whereas declined to normal after IVIG therapy; it was positively correlated with C-reactive protein and erythrocyte sedimentation rate. (2) Serum IL-6 was significantly elevated in patients with incomplete KD when compared with their complete counterparts. The area under receiver operating characteristic curve (AUC) value for serum IL-6 in prediction of incomplete KD was 0.596, and the estimated sensitivity and specificity were 77.80% and 54.40% with a cutoff of IL-6 > 13.25 pg/ml, respectively. (3) Serum IL-6 was significantly elevated in patients with IVIG-nonresponsive KD when compared with their IVIG-responsive counterparts; the AUC value for serum IL-6 in prediction of IVIG-nonresponsive KD was 0.580, and the estimated sensitivity and specificity were 60.00% and 66.30% with a cutoff of IL-6 > 26.40 pg/ml, respectively. (4) No significant differences in IL-6 were found between KD patients with and without CAA. IL-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive KD rather than CAA.


Interleukin-6 Intravenous immunoglobulin Kawasaki disease Vascular endothelial cell Coronary artery aneurysm 



At the point of finishing this paper, we thank Dr Bo Hu, Dr Xiao Chen Fan and Dr Shan Zhi Yang for their valuable helps in study design and technical performance.


This study was supported by the New Technology Project of the First Affiliated Hospital, Anhui Medical University (2014-01).

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest relevant to this article to disclose.

Ethical approval

Approval for this research was acquired from the Medical Ethic Committee of the First Affiliated Hospital of Anhui Medical University.

Informed consent

Consent was obtained from parents.


  1. 1.
    Chen JJ, Ma XJ, Liu F, et al. Epidemiologic features of Kawasaki disease in Shanghai from 2008 through 2012. Pediatr Infect Dis J. 2016;35:7–12.Google Scholar
  2. 2.
    Crindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–99.Google Scholar
  3. 3.
    Daniels LB, Tjajadi MS, Walford HH, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia. Circulation. 2012;125:2447–53.CrossRefGoogle Scholar
  4. 4.
    Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341–7.CrossRefGoogle Scholar
  5. 5.
    Xiu-Yu S, Jia-Yu H, Qiang H, Shu-Hui D. Platelet count and erythrocyte sedimentation rate are good predictors of Kawasaki disease: ROC analysis. J Clin Lab Anal. 2010;24:385–8.CrossRefGoogle Scholar
  6. 6.
    Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20:87–103.CrossRefGoogle Scholar
  7. 7.
    Hu P, Jiang GM, Wu Y, et al. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease. Clin Chim Acta. 2017;471:76–80.CrossRefGoogle Scholar
  8. 8.
    Wang Y, Wang W, Gong F, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum. 2013;65:805–14.CrossRefGoogle Scholar
  9. 9.
    Song MS, Lee SB, Sohn S, et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J. 2010;40:334–8.CrossRefGoogle Scholar
  10. 10.
    Mesquida M, Molins B, Llorenç V, de la Maza MS, Adán A. Targeting interleukin-6 in autoimmune uveitis. Autoimmun Rev. 2017;16:1079–89.CrossRefGoogle Scholar
  11. 11.
    Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E. A review of recent advances using Tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5:21–42.CrossRefGoogle Scholar
  12. 12.
    Spîrchez M, Samaşca G, Iancu M, Bolba C, Miu N. Relation of interleukin-6, TNF-alpha and interleukin-1α with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab. 2012;58:253–60.Google Scholar
  13. 13.
    Lai JM, Wu FQ, Zhou ZX, et al. Tocilizumab for refractory systemic juvenile idiopathic arthritis. Zhonghua Er Ke Za Zhi. 2017;55:830–4.Google Scholar
  14. 14.
    Suganami Y, Kawashima H, Hasegawa D, Sato S, Hoshika A. Clinical application of rapid assay of serum interleukin-6 in Kawasaki disease. Pediatr Int. 2008;50:264–6.CrossRefGoogle Scholar
  15. 15.
    Cai XY, Lu Y, Tang C, et al. Effect of interleukin-6 promoter DNA methylation on the pathogenesis of systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi. 2017;97:1491–5.Google Scholar
  16. 16.
    Yasuda H, Ikeda T, Hamaguchi Y, Furukawa F. Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: the relation between the disease activity and the serum interleukin-6 level. J Dermatol. 2017;44:1164–7.CrossRefGoogle Scholar
  17. 17.
    Palizgir MT, Akhtari M, Mahmoudi M, Mostafaei S, Rezaiemanesh A, Shahram F. Curcumin reduces the expression of interleukin 1β and the production of interleukin 6 and tumor necrosis factor alpha by M1 macrophages from patients with Behcet’s disease. Immunopharmacol Immunotoxicol. 2018;40:297–302.CrossRefGoogle Scholar
  18. 18.
    Ye Q, Shao WX, Shang SQ, Zhang T, Hu J, Zhang CC. A comprehensive assessment of the value of laboratory indices in diagnosing Kawasaki disease. Arthritis Rheumatol. 2015;67:1943–50.CrossRefGoogle Scholar
  19. 19.
    Kim DS. Serum interleukin-6 in Kawasaki disease. Yonsei Med J. 1992;33:183–8.CrossRefGoogle Scholar
  20. 20.
    Higa M, Oka M, Fujihara Y, Masuda K, Yoneda Y, Kishimoto T. Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. Proc Natl Acad Sci USA. 2018;115:E1214–20.CrossRefGoogle Scholar
  21. 21.
    Masuda K, Ripley B, Nishimura R, et al. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc Natl Acad Sci USA. 2013;110:9409–14.CrossRefGoogle Scholar
  22. 22.
    Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr. 1992;121:924–6.CrossRefGoogle Scholar
  23. 23.
    Peng Q, Wu Q, Chen CH, Hong H, Zhang LY. Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi. 2006;8:208–10.Google Scholar
  24. 24.
    Beringer A, Thiam N, Molle J, Bartosch B, Miossec P. Synergistic effect of interleukin-17 and tumour necrosis factor-α on inflammatory response in hepatocytes through interleukin-6-dependent and independent pathways. Clin Exp Immunol. 2018;193:221–33.CrossRefGoogle Scholar
  25. 25.
    Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339–42.CrossRefGoogle Scholar
  26. 26.
    Ha KS, Jang G, Lee J, et al. Incomplete clinical manifestation as a risk factor for coronary artery abnormalities in Kawasaki disease: a meta-analysis. Eur J Pediatr. 2013;172:343–9.CrossRefGoogle Scholar
  27. 27.
    Liu HC, Lo CW, Hwang B, Lee PC. Clinical manifestations vary with different age spectrums in infants with Kawasaki disease. Sci World J. 2012;2012:210382.Google Scholar
  28. 28.
    Bai L, Feng T, Yang L, et al. Retrospective analysis of risk factors associated with Kawasaki disease in China. Oncotarget. 2017;8:54357–63.Google Scholar
  29. 29.
    Peng C, Luo YJ, Xing QL, Xiao MC. Clinical features of children with incomplete Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18:1111–4.Google Scholar
  30. 30.
    Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606–12.CrossRefGoogle Scholar
  31. 31.
    Baek JY, Song MS. Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Korean J Pediatr. 2016;59:80–90.CrossRefGoogle Scholar
  32. 32.
    Kim MK, Song MS, Kim GB. Factors predicting resistance to intravenous immunoglobulin treatment and coronary artery lesion in patients with Kawasaki disease: analysis of the Korean Nationwide Multicenter Survey from 2012 to 2014. Korean Circ J. 2018;48:71–9.CrossRefGoogle Scholar
  33. 33.
    Xie T, Wang Y, Fu S, et al. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease. Pediatr Rheumatol Online J. 2017;15:17.CrossRefGoogle Scholar
  34. 34.
    Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol. 2001;21:193–9.CrossRefGoogle Scholar
  35. 35.
    Ikeda K, Mizoro Y, Ameku T, et al. Transcriptional analysis of intravenous immunoglobulin resistance in Kawasaki disease using an induced pluripotent stem cell disease model. Circ J. 2016;81:110–8.CrossRefGoogle Scholar
  36. 36.
    Maric LS, Knezovic I, Papic N, et al. Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience. Rheumatol Int. 2015;35:1053–8.CrossRefGoogle Scholar
  37. 37.
    Si F, Wu Y, Gao F, et al. Relationship between IL-27 and coronary arterial lesions in children with Kawasaki disease. Clin Exp Med. 2017;17:451–7.CrossRefGoogle Scholar
  38. 38.
    Lee GL, Wu JY, Tsai CS, et al. TLR4-activated MAPK-IL-6 axis regulates vascular smooth muscle cell function. Int J Mol Sci. 2016;17:E1394.CrossRefGoogle Scholar
  39. 39.
    Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation. 2005;111:38–43.CrossRefGoogle Scholar
  40. 40.
    Nozawa T, Imagawa T, Ito S. Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki’s disease. N Engl J Med. 2017;377:1894–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Yue Wu
    • 1
  • Fei Fei Liu
    • 1
  • Yao Xu
    • 1
  • Jing Jing Wang
    • 1
  • Sama Samadli
    • 1
  • Yang Fang Wu
    • 1
  • Hui Hui Liu
    • 1
  • Wei Xia Chen
    • 1
  • Huang Huang Luo
    • 1
  • Dong Dong Zhang
    • 1
  • Wei Wei
    • 1
  • Peng Hu
    • 1
    Email author
  1. 1.Department of Pediatricsthe First Affiliated Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China

Personalised recommendations